THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.27] ID: TIP-MED-000027

Nifedipine (Sustained-Release / Osmotic-Release)

Active Ingredient / Scientific Identity: Nifedipine • Class: Dihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM 2022)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Nifedipine (Sustained-Release / Osmotic-Release) ([3.27] | ID: TIP-MED-000027) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-27-nifedipine-sustained-release-osmotic-release/
Generic / Entity NameNifedipine (Sustained-Release / Osmotic-Release) ([3.27])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassDihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM 2022)
Available Dosage FormsSR/Retard Tablets: 10 mg, 20 mg; Osmotic/CD/XL Tablets: 30 mg, 60 mg (Immediate-release capsules should NOT be
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Safe in all CKD stages (no adjustment). Hepatic: Reduce dose by 50% in Child–Pugh B/C cirrhosis
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Nifedipine (Sustained-Release / Osmotic-Release) (TIP-MED-000027, Reference Code [3.27]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Dihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.27], p. 34): Nicardia Retard / CD (JB Chemicals), Depin Retard (Zydus), Calcigard Retard (Torrent) — Strengths & Dosage Forms: SR/Retard Tablets: 10 mg, 20 mg; Osmotic/CD/XL Tablets: 30 mg, 60 mg (Immediate-release capsules should NOT be used sublingually for HTN urgency)
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.27], p. 34): Nicardia Retard / CD (JB Chemicals), Depin Retard (Zydus), Calcigard Retard (Torrent) — Strengths & Dosage Forms: SR/Retard Tablets: 10 mg, 20 mg; Osmotic/CD/XL Tablets: 30 mg, 60 mg (Immediate-release capsules should NOT be used sublingually for HTN urgency)
Dosage Forms & Available Strengths:
SR/Retard Tablets: 10 mg, 20 mg; Osmotic/CD/XL Tablets: 30 mg, 60 mg (Immediate-release capsules should NOT be used sublingually for HTN urgency)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Dihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Dihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM 2022) for Essential hypertension, chronic stable/vasospastic angina, gestational hypertension / pre-eclampsia (first-line safe in pregnancy), Raynaud phenomenon.

4. Therapeutic Indications & Evidence-Supported Uses

  • Essential hypertension, chronic stable/vasospastic angina, gestational hypertension / pre-eclampsia (first-line safe in pregnancy), Raynaud phenomenon

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: HTN/Angina: 10–20 mg SR BD or 30–60 mg XL/CD OD (Max 60–90 mg/day). Pre-eclampsia: 10–20 mg SR PO BD–TDS

Administration & Meal Timing: Swallow SR/Retard/XL tablets WHOLE with water; NEVER crush, chew, or bite open capsules | Morning & Evening (12-hourly for Retard/SR) or Morning (OD for XL/CD)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Safe in all CKD stages (no adjustment). Hepatic: Reduce dose by 50% in Child–Pugh B/C cirrhosis
Elimination & Renal Adjustment:
Renal: Safe in all CKD stages (no adjustment). Hepatic: Reduce dose by 50% in Child–Pugh B/C cirrhosis
Hepatic Impairment Considerations:
Renal: Safe in all CKD stages (no adjustment). Hepatic: Reduce dose by 50% in Child–Pugh B/C cirrhosis

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in cardiogenic shock, severe aortic stenosis, and acute MI; NEVER use sublingual IR Nifedipine (causes precipitous hypotension, stroke, & MI!)

Key Clinical Precautions: Renal: Safe in all CKD stages (no adjustment). Hepatic: Reduce dose by 50% in Child–Pugh B/C cirrhosis

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Flushing, headache, palpitations, dose-dependent ankle oedema, constipation, dizziness
  • Severe hypotension, myocardial ischaemia from reflex tachycardia (if IR used), gingival hyperplasia
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Rifampicin/Phenytoin markedly reduce Nifedipine bioavailability; potentiates IV Magnesium Sulfate neuromuscular/hypotensive effects in pre-eclampsia

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Swallow Retard/XL tablets whole; non-digestible osmotic shell may appear intact in stool (normal); safe in pregnancy & lactation
  • Meal & Clock Timing Instruction: Swallow SR/Retard/XL tablets WHOLE with water; NEVER crush, chew, or bite open capsules (Morning & Evening (12-hourly for Retard/SR) or Morning (OD for XL/CD))
  • Missed Dose Protocol: Take within 6 hours if BD; skip if close to next dose; never crush or double dose
  • Geriatric Dispensing Pearl: Avoid short-acting formulations in older adults (AGS Beers 2023); use only long-acting SR/XL and monitor orthostatic BP

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: SR/Retard Tablets: 10 mg, 20 mg; Osmotic/CD/XL Tablets: 30 mg, 60 mg (Immediate-release capsules should NOT be used sublingually for HTN urgency)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.27] (p. 34)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-27-nifedipine-sustained-release-osmotic-release/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.